Cell Survival and Metastasis Regulation by Akt Signaling in Colorectal Cancer

Overview

Journal Cell Signal

Date 2013 Apr 23

PMID 23603750

Citations 76

Authors

Ekta Agarwal

Michael G Brattain

Sanjib Chowdhury

Affiliations

Soon will be listed here.

Abstract

Dissemination of cancer cells to distant organ sites is the leading cause of death due to treatment failure in different types of cancer. Mehlen and Puisieux have reviewed the importance of the development of inappropriate cell survival signaling for various steps in the metastatic process and have noted the particular importance of aberrant cell survival to successful colonization at the metastatic site. Therefore, the understanding of mechanisms that govern cell survival fate of these metastatic cells could lead to the understanding of a new paradigm for the control of metastatic potential and could provide the basis for developing novel strategies for the treatment of metastases. Numerous studies have documented the widespread role of Akt in cell survival and metastasis in colorectal cancer, as well as many other types of cancer. Akt acts as a key signaling node that bridges the link between oncogenic receptors to many essential pro-survival cellular functions, and is perhaps the most commonly activated signaling pathway in human cancer. In recent years, Akt2 and Akt3 have emerged as significant contributors to malignancy alongside the well-characterized Akt1 isoform, with distinct non-overlapping functions. This review is aimed at gaining a better understanding of the Akt-driven cell survival mechanisms that contribute to cancer progression and metastasis and the pharmacological inhibitors in clinical trials designed to counter the Akt-driven cell survival responses in cancer.

Citing Articles

Synthesis of a new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAF inhibitors.

Al-Wahaibi L, Youssif B, Abou-Zied H, Brase S, Brown A, Tawfeek H RSC Med Chem. 2024; 15(7):2538-2552.

PMID: 39026636 PMC: 11253863. DOI: 10.1039/d4md00230j.

Exploring the influence of microgravity on chemotherapeutic drug response in cancer: Unveiling new perspectives.

Vora P, Prabhu S J Cell Mol Med. 2024; 28(9):e18347.

PMID: 38693857 PMC: 11063729. DOI: 10.1111/jcmm.18347.

Role of EGFR and FASN in breast cancer progression.

Chaturvedi S, Biswas M, Sadhukhan S, Sonawane A J Cell Commun Signal. 2023; 17(4):1249-1282.

PMID: 37490191 PMC: 10713975. DOI: 10.1007/s12079-023-00771-w.

A novel anoikis-related risk model predicts prognosis in patients with colorectal cancer and responses to different immunotherapy strategies.

Yang L, Xu F J Cancer Res Clin Oncol. 2023; 149(12):10879-10892.

PMID: 37318595 DOI: 10.1007/s00432-023-04945-2.

Development of Green and High Throughput Microplate Reader-Assisted Universal Microwell Spectrophotometric Assay for Direct Determination of Tyrosine Kinase Inhibitors in Their Pharmaceutical Formulations Irrespective the Diversity of Their Chemical....

Darwish I, Alzoman N Molecules. 2023; 28(10).

PMID: 37241790 PMC: 10223063. DOI: 10.3390/molecules28104049.

References

Kuo Y, Huang K, Yang C, Yang Y, Lee W, Chiang C . Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2007; 283(4):1882-92. DOI: 10.1074/jbc.M709585200. View

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R . The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer. 2000; 87(3):336-42. View

Chung S, Yao J, Suyama K, Bajaj S, Qian X, Loudig O . N-cadherin regulates mammary tumor cell migration through Akt3 suppression. Oncogene. 2012; 32(4):422-30. PMC: 4351658. DOI: 10.1038/onc.2012.65. View

Chen M, Wu X, Tao G, Liu C, Chen J, Wang L . Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. Int J Cancer. 2012; 131(11):2487-98. DOI: 10.1002/ijc.27548. View

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M . YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67(17):8014-21. DOI: 10.1158/0008-5472.CAN-07-1343. View

Coffer P, Woodgett J . Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1992; 205(3):1217. View

Levy D, Kahana J, Kumar R . AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood. 2008; 113(8):1723-9. DOI: 10.1182/blood-2008-02-137737. View

10.

Chowdhury S, Howell G, Rajput A, Teggart C, Brattain L, Weber H . Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One. 2011; 6(5):e19335. PMC: 3086924. DOI: 10.1371/journal.pone.0019335. View

11.

Pinton G, Manente A, Angeli G, Mutti L, Moro L . Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One. 2012; 7(5):e36856. PMC: 3349630. DOI: 10.1371/journal.pone.0036856. View

12.

Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M . Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002; 94(12):3127-34. DOI: 10.1002/cncr.10591. View

13.

Chung D . The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000; 119(3):854-65. DOI: 10.1053/gast.2000.16507. View

14.

Mehrotra S, Languino L, Raskett C, Mercurio A, Dohi T, Altieri D . IAP regulation of metastasis. Cancer Cell. 2010; 17(1):53-64. PMC: 2818597. DOI: 10.1016/j.ccr.2009.11.021. View

15.

Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D . Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011; 29(32):4243-9. DOI: 10.1200/JCO.2010.33.9788. View

16.

Gorlick R, Maris J, Houghton P, Lock R, Carol H, Kurmasheva R . Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2011; 59(3):518-24. PMC: 3290691. DOI: 10.1002/pbc.23412. View

17.

de Frias M, Iglesias-Serret D, Cosialls A, Coll-Mulet L, Santidrian A, Gonzalez-Girones D . Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009; 94(12):1698-707. PMC: 2791940. DOI: 10.3324/haematol.2008.004028. View

18.

Floryk D, Thompson T . Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett. 2008; 266(2):216-26. PMC: 2525810. DOI: 10.1016/j.canlet.2008.02.060. View

19.

Gilot D, Giudicelli F, Lagadic-Gossmann D, Fardel O . Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway. Chem Biol Interact. 2010; 188(3):546-52. DOI: 10.1016/j.cbi.2010.08.011. View

20.

Yoeli-Lerner M, Toker A . Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006; 5(6):603-5. DOI: 10.4161/cc.5.6.2561. View